MTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Matsubara, Shyuichiro ^a   Ding, Qiang ^a   Miyazaki, Yumi ^a   Kuwahata, Taisaku ^b   Tsukasa, Koichiro ^a   Takao, Sonshin ^a  

^a Cancer and Regenerative Medicine   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CYCLOPAMINE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; RAPAMYCIN; SONIC HEDGEHOG PROTEIN; TARGET OF RAPAMYCIN KINASE; VERATRUM ALKALOID;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER STEM CELL; CELL SURVIVAL; DRUG EFFECTS; HUMAN; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELL SURVIVAL; GLYCOPROTEINS; HEDGEHOG PROTEINS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; VERATRUM ALKALOIDS;

EID: 84889572662     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03230     Document Type: Article

References (60)

1. Dean, M. Cancer stem cells: Implications for cancer causation and therapy resistance. Discov. Med. 5, 278-282 (2005)
2. Eyler, C. E. & Rich, J. N. Survival of the fittest: Cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 26, 2839-2845 (2008)
3. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007) (Pubitemid 47355323)
4. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006) (Pubitemid 44949604)
5. Jimeno, A. et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther. 8, 310-314 (2009)
6. Lee, C. J., Dosch, J.&Simeone, D. M. Pancreatic cancer stem cells. J Clin Oncol. 26, 2806-2812 (2008)
7. Todaro, M. et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389-402 (2007) (Pubitemid 47506537)
8. Morris 4th, J. P.,Wang, S. C.&Hebrok, M. KRAS,Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683-695 (2010)
9. Chan, T. O. et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell 1, 181-191 (2002) (Pubitemid 41039164)
10. Kennedy, A. L., Adams, P. D. & Morton, J. P. Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy. Small Gtpases. 2, 264-267 (2011)
11. Semba, S., Moriya, T., Kimura, W. & Yamakawa, M. Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor 1and invasive ductal adenocarcinoma of the pancreas. Pancreas 26, 250-257 (2003) (Pubitemid 36384157)
12. Asano, T. et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580 (2004) (Pubitemid 39576463)
13. Michl, P. & Downward, J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z. Gastroenterol. 43, 1133-1139 (2005) (Pubitemid 41584815)
14. Kennedy, A. L. et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol. Cell 42, 36-49 (2011)
15. Guertin, D. A. & Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007) (Pubitemid 47001784)
16. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006)
17. Takahashi, K., Murakami, M. & Yamanaka, S. Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem. Soc. Trans. 33, 1522-1525 (2005) (Pubitemid 41779729)
18. Yamano, N., Kimura, T., Watanabe-Kushima, S., Shinohara, T. & Nakano, T. Metastable primordial germ cell-like state induced from mouse embryonic stem cells by Akt activation. Biochem. Biophys. Res. Commun. 392, 311-316 (2010)
19. Zhou, J. et al. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc. Natl. Acad. Sci. USA 106, 7840-7845 (2009)
20. Murakami, M. et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol. Cell Biol. 24, 6710-6718 (2004) (Pubitemid 38944350)
21. Gangloff, Y. G. et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol. Cell Biol. 24, 9508-9516 (2004)
22. Schieke, S. M. et al. Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J. Biol. Chem. 283, 28506-28512 (2008)
23. Gregorian, C. et al. Pten deletion in adult neural stem/progenitor cells enhances constitutive neurogenesis. J. Neurosci. 29, 1874-1886 (2009)
24. Groszer, M. et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294, 2186-2189 (2001) (Pubitemid 33150679)
25. Groszer, M. et al. PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc. Natl. Acad. Sci. USA 103, 111-116 (2006) (Pubitemid 43076113)
26. Sunayama, J. et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro. Oncol. 12, 1205-1219 (2010)
27. Ding, Q. et al. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Hum. Cell 25, 1-8 (2012)
28. Hayashi, T. et al. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci. 103, 889-896 (2012)
29. Mueller, M. T. et al. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137, 1102-1113 (2009)
30. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008) (Pubitemid 351636299)
31. Hsu, H. S. et al. Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung Cancer 75, 167-177 (2011)
32. Hwang, W. L. et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology 141, 279-291 (2011)
33. Lathia, J. D. et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis. 2, e200, doi: 10.1038/cddis.2011.80. (2011)
34. Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (2006) (Pubitemid 43668737)
35. Harrington, L. S. et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223 (2004) (Pubitemid 38988774)
36. Hsu, P. P. et al. The mTOR-regulated phosphoproteome leveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-1322 (2011)
37. Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-1326 (2011)
38. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005) (Pubitemid 40262113)
39. Sunayama, J. et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells 28, 1930-1939 (2010)
40. Bruns, C. J., Harbison, M. T., Kuniyasu, H., Eue, I. & Fidler, I. J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1, 50-62 (1999)
41. Naumann, M. et al. Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology 110, 1215-1224 (1996) (Pubitemid 26113762)
42. Barton, C. M. et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 64, 1076-1082 (1991)
43. Kalthoff, H. et al. p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 8, 289-298 (1993) (Pubitemid 23073744)
44. Berrozpe, G., Schaeffer, J., Peinado, M. A., Real, F. X. & Perucho, M. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int. J. Cancer 58, 185-191 (1994) (Pubitemid 24240093)
45. Schutte, M. et al. DPC4 gene in various tumor types. Cancer Res. 56, 2527-2530 (1996) (Pubitemid 26170688)
46. Moore, P. S., Beghelli, S., Zamboni, G. & Scarpa, A. Genetic abnormalities in pancreatic cancer. Mol. Cancer 2, 7, doi: 10.1186/1476-4598-2-7 (2003) (Pubitemid 38751490)
47. Loukopoulos, P. et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29, 193-203 (2004) (Pubitemid 39304976)
48. Moore, P. S. et al. Pancreatic tumours: Molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br. J. Cancer 84, 253-262 (2001) (Pubitemid 32113454)
49. Rozenblum, E. et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57, 1731-1734 (1997) (Pubitemid 27199667)
50. Ying, H. et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kB-cytokine network. Cancer Discov. 1, 158-169 (2011)
51. Dan, H. C. et al. Akt-dependent regulation of NF-kB is controlled by mTOR and Raptor in association with IKK. Genes & Dev. 22, 1490-1500 (2008) (Pubitemid 351793083)
52. Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346-354 (2013)
53. Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196 (2007) (Pubitemid 46424238)
54. Feldmann, G. et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 7, 2725-2735 (2008)
55. Fu, J. et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 330, 22-32 (2013)
56. Yilmaz, O. H. et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482 (2006) (Pubitemid 44050144)
57. Guertin, D. A. et al. mTOR complex 2 is required for the development of prostate cancer induced by PTEN loss in mice. Cancer Cell 15, 148-159 (2009)
58. Martelli, A. M. et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr. Med. Chem. 18, 2715-2726 (2011)
59. Lee, J. Y. et al. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. Cell Stem Cell 7, 593-605 (2010)
60. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685 (1970)